|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study reveals that H19, but not MALAT1 and GAS5, may be a useful marker of response to NAC in BC.
|
31640083 |
2020 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs145204276 del allele might protect against the development of BC via inducing the promoter activity by binding to transcriptional factor specificity protein 1, and finally resulting in higher levels of GAS5.
|
30846409 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we showed that miR-221/222 suppressed GAS5 expression significantly and enhanced tumor growth in a mouse model of breast cancer xenografts.
|
30538172 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of breast cancer-related GAS5 and LSINCT5 lncRNAs in cancer-free breast tissue: Molecular associations with age at menarche and obesity.
|
29785740 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our study demonstrates that GAS5 enhances the efficacy of tamoxifen in the treatment of breast cancer and could be a novel prognostic biomarker.
|
29969658 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the competing endogenous RNA (ceRNA)-dependent mechanism by which the lncRNA GAS5 contributes to the development of breast cancer.
|
30007957 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we focused on the roles of GAS5 in the anti-cancer effects of DNC on breast cancer.
|
29655698 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the lncRNA GAS5 was decreased in SKBR-3/Tr cells and in breast cancer tissue from trastuzumab-treated patients.
|
27034004 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with paired preoperative plasma, the postoperative levels of GAS5 and H19 significantly decreased in 71.8 % of BC patients (28/39) and 82.1 % of BC patients (32/39), respectively.
|
26662314 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nucleofection of hormone-sensitive and -insensitive breast cancer cell lines with a GAS5 HREM DNA oligonucleotide increased both basal and ultraviolet-C-induced apoptosis, and decreased culture viability and clonogenic growth, similar to GAS5 lncRNA.
|
26862727 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LncRNA GAS5 is a recently identified tumor suppressor involved in several cancers, like breast cancer, prostate cancer, lung cancer, and colorectal cancer.
|
26634743 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast cancer cell lines were transfected with either siRNA to GAS5 or with a plasmid encoding GAS5 lncRNA and the effects on breast cancer cell survival were determined.
|
24789445 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have revealed that long non-coding RNAs (lncRNAs) play important roles in cancer biology and that lncRNA gas5 (growth arrest-specific 5) regulates breast cancer cell growth.
|
24026436 |
2013 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer.
|
18836484 |
2009 |